{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:00:14Z","timestamp":1794492014703,"version":"4.9.1"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,12,10]],"date-time":"2004-12-10T00:00:00Z","timestamp":1102636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Several modalities have been used for the treatment of cutaneous leishmaniasis (CL) with various results.\n                    <jats:italic>In vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    studies have shown inhibitory effects of azole drugs on\n                    <jats:italic>Leishmania<\/jats:italic>\n                    parasites.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives\u2002<\/jats:bold>\n                    To evaluate the efficacy and tolerability of oral itraconazole in the treatment of CL caused by\n                    <jats:italic>L. major<\/jats:italic>\n                    .\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    A total of 200 patients with parasitologically confirmed CL with a duration of less than 45\u00a0days from a well known\n                    <jats:italic>L. major<\/jats:italic>\n                    endemic area were included in a randomized, double\u2010blind, placebo\u2010controlled clinical trial. The patients received either itraconazole 200\u00a0mg daily (100 patients) or placebo (100 patients) for 8\u00a0weeks. The primary outcome measures were clinical cure (complete re\u2010epithelization of all lesions) and parasitological cure at the end of the treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Eighty\u2010three patients in the itraconazole and 75 patients in the placebo group completed the treatment course. After 8\u00a0weeks of treatment, clinical cure was observed in 59% and 53% and parasitological cure was observed in 83% and 76% of patients in the itraconazole and placebo groups, respectively, which were not significantly different. There was no difference in the rate of adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    An 8\u2010week course of oral itraconazole was not more effective than placebo in the treatment of CL.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2004.01133.x","type":"journal-article","created":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T04:43:50Z","timestamp":1105418630000},"page":"80-83","source":"Crossref","is-referenced-by-count":73,"title":["A randomized, double\u2010blind, placebo\u2010controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis"],"prefix":"10.1111","volume":"19","author":[{"given":"M","family":"Nassiri\u2010Kashani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Firooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Mojtahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nilforoushzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Bouzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,12,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081X(96)00057-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081X(96)00058-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081X(96)00047-8"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(89)90026-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.3.528"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90292-L"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011882"},{"key":"e_1_2_6_9_2","first-page":"568","article-title":"Cutaneous leishmaniasis in India: evaluation of oral drugs (dapsone versus itraconazole)","volume":"8","author":"Dogra J","year":"1992","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1991.tb04878.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890310070009"},{"key":"e_1_2_6_12_2","first-page":"7","article-title":"Identification of Leishmania species using monoclonal antibodies in Esfahan","volume":"4","author":"Hejazi H","year":"2000","journal-title":"Iranian J Dermatol"},{"key":"e_1_2_6_13_2","first-page":"596","article-title":"Ketoconazole in cutaneous leishmaniasis: results of a pilot study","volume":"7","author":"Kubba R","year":"1986","journal-title":"Saudi Med J"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00417211"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb00622.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_1.S57"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1994.tb01049.x"},{"key":"e_1_2_6_18_2","first-page":"612.1","volume-title":"Recent Advances in Chemotherapy","author":"De Beule K","year":"1989"},{"key":"e_1_2_6_19_2","first-page":"20","article-title":"Cutaneous leishmaniasis in Kuwait: part II. Therapeutic trial of rifampicin and pentostam","volume":"4","author":"Hafez J","year":"1985","journal-title":"Arab J Med"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2004.01133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2004.01133.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T01:24:41Z","timestamp":1696987481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2004.01133.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,10]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1468-3083.2004.01133.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2004.01133.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,10]]}}}